Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptomsopen access
- Authors
- Kim, Kyu Shik; Moon, Hong Sang
- Issue Date
- Dec-2016
- Publisher
- KOREAN CONTINENCE SOC
- Keywords
- Urinary Bladder; Overactive; Depression; Quality of Life
- Citation
- INTERNATIONAL NEUROUROLOGY JOURNAL, v.20, no.4, pp.349 - 355
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- INTERNATIONAL NEUROUROLOGY JOURNAL
- Volume
- 20
- Number
- 4
- Start Page
- 349
- End Page
- 355
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153451
- DOI
- 10.5213/inj.1624678.339
- ISSN
- 2093-4777
- Abstract
- Purpose
We investigated improvements in overactive bladder symptoms and depressive symptoms after solifenacin treatment in overactive bladder patients with or without depressive symptoms.
Methods
We performed a prospective study of patients who had been diagnosed with overactive bladder from July 2013 to June 2014. Based on the Beck Depression Inventory questionnaire, the test subjects were divided into group 1, without depressive symptoms (0–9 points), and group 2, with depressive symptoms (10 or more points). The patients were administered 5 mg of solifenacin for 3 months. The following outcomes were analyzed at the first visit, 4 weeks, and 12 weeks: the overactive bladder symptom score (OABSS), International Prostate Symptom Score (IPSS), patients’ perceptions of their bladder condition, and the Beck Depression Inventory.
Results
A total of 72 patients participated, and 52 patients completed the study. Most outcome measures showed improvements in both groups at weeks 4 and 12. Especially in group 2, the questionnaires showed significant improvements from baseline to week 12, indicating that solifenacin was effective at treating overactive bladder symptoms (group 1 vs. group 2: OABSS, −2.67±0.80 vs. −3.00±0.77; P<0.01; IPSS-total, −2.14±2.15 vs. −4.94±1.70; P<0.01). Statistically significant decreases in the Beck Depression Inventory score from baseline to weeks 4 and 12 were observed in group 2 (group 1 vs. group 2: 1.43±0.74 vs. −2.68±4.05 at week 4, P<0.001; 0.10±3.37 vs. −5.52±5.82 at week 12, P<0.001).
Conclusions
In overactive bladder patients with depressive symptoms, solifenacin can help improve quality of life and depressive symptoms at the same time.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 비뇨의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153451)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.